Slide 1: Teleflex Incorporated First Quarter 2010 Conference Call
TELEFLEX INCORPORATED FIRST QUARTER 2010 CONFERENCE CALL Exhibit 99.1
Slide 2: Forward-Looking Statements/Additional Notes
2 2 Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, expected improvements in surgical sales during the second half of 2010; upcoming 2010 Medical Segment product launches; expected impr
Slide 3: Conference Call Logistics
3 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls, 617- 801-6888, pass code number 40498357
Slide 4: Jeff Black, Chairman and Chief Executive Officer
4 JEFF BLACK Chairman and Chief Executive Officer
Slide 5: First Quarter Financial Highlights
5 First Quarter Financial Highlights Revenue of $436.5 million versus $440.1 million in the prior year quarter Down 1% as reported; down 3% on a constant currency basis Medical: $343.5 - 79% of total revenue Aerospace: $36.9 - 8% of total revenue Commercial: $56.1 - 13% of total revenue Adjusted gro
Slide 6: Medical Segment
6 Medical Segment Critical Care - $225.9 million - Core Revenue Growth of 1% Vascular core revenue decline due to IV tubing recall; excluding recall, vascular core revenue growth of 2% Anesthesia core growth continues to be driven by regional anesthesia product offerings; recently launched ISIS endo
Slide 7: New Product Introduction Update
7 New Product Introduction Update Launched in First Quarter 2010 Anesthesia: Teleflex ISIS TM HVT TM endotracheal tube Surgical: Deklene Maxx specialty cardiovascular suture Respiratory: Combined HEPA / HME Upcoming 2010 Product Launches Vascular Access: Anti-microbial coated PICC Vascular Access: P
Slide 8: FDA Update
8 FDA Update At the end of 2009, the FDA began its re-inspections of the former-Arrow facilities covered by the corporate warning letter These inspections have been completed FDA has issued certain written observations as a result of the inspections We have responded in writing to those observations
Slide 9: Aerospace Segment
9 Cargo Systems & Actuation OEM wide-body sales up due to increased shipments of cargo loading systems to Boeing & Airbus; offset slightly by decline in aftermarket conversions Narrow-body cargo loading system unit volume down ~ 20% from Q1'09 High margin spares sales down approximately $3M from Q1'
Slide 10: Commercial Segment
10 Commercial Segment Marine Core revenues up 17% versus prior year quarter Aftermarket revenue up 11% versus prior year quarter OEM revenue up 64% versus prior year quarter; up sequentially Gauge divestiture impacts revenue by approx. $2.6M Improved aftermarket and OEM volumes and full year impact
Slide 11: Randy Meier, Executive Vice President and Chief Financial Officer
11 RANDY MEIER Executive Vice President and Chief Financial Officer
Slide 12: First Quarter Income Statement from Continuing Operations
12 First Quarter Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 13: First Quarter EPS Reconciliation from Continuing Operations
13 First Quarter EPS Reconciliation from Continuing Operations Note: Q1'09 losses and other charges includes loss on sale of Gauge business of $1.6m, net of tax and integration costs of $0.4m, net of tax
Slide 14: Year-to-Date Adjusted Cash Flow From Continuing Operations
14 Year-to-Date Adjusted Cash Flow From Continuing Operations ($ Millions) Capital Expenditures - $6.5 million Capital Expenditures - $7.2 million
Slide 15: 2010 Total Company Outlook
15 2010 Total Company Outlook
Slide 16: 2010 Segment Outlook
6 2010 Segment Outlook Updated FY'10 Outlook Previous FY'10 Outlook Revenue ‘Segment Operating Margins Core Revenue Growth Revenue ‘Segment Operating Margins (Core Revenue Growth Revenue ‘Segment Operating Margins CCore Revenue Growth ~s1470 ~ 20% 3% s180- st8s Low double-digit (8%) - Fat $230- $240
Slide 17: Question & Answer
QUESTION & ANSWER Teleflex:
Slide 18: Appendices
APPENDICES Teleflex:
Slide 19: Appendix A - Reconciliation of Medical Operating Profit and Margins
19 Appendix A - Reconciliation of Medical Operating Profit and Margins
Slide 20: Appendix B - Reconciliation of Teleflex Gross Profit and Margins
20 Appendix B - Reconciliation of Teleflex Gross Profit and Margins
Slide 21: Appendix C - Reconciliation of Teleflex Selling, Engineering and Administrative Expenses
21 Appendix C - Reconciliation of Teleflex Selling, Engineering and Administrative Expenses
Slide 22: Appendix D - Reconciliation of Teleflex Operating Expenses
22 Appendix D - Reconciliation of Teleflex Operating Expenses
Slide 23: Appendix E - Special Charge Income Statement Classification Summary
23 Appendix E - Special Charge Income Statement Classification Summary
Slide 24: Appendix F - Reconciliation of Teleflex Cash Flow from Continuing Operations
24 Appendix F - Reconciliation of Teleflex Cash Flow from Continuing Operations
Slide 25: Appendix G - Reconciliation of Teleflex Cash EPS Excluding Special Charges
25 Appendix G - Reconciliation of Teleflex Cash EPS Excluding Special Charges